Inflammatory markers of cardiovascular disease risk in Portuguese psoriatic patients: Relation with narrow-band ultraviolet B and psoralen plus ultraviolet A

International Journal of Dermatology

Volumn 53, Issue 3, 2014, Pages 393-396

  Coimbra, Susana ^a,b   Oliveira, Hugo ^c   Neuparth, Maria J ^b,d   Figueiredo, Américo ^c   Rocha Pereira, Petronila ^a,e   Santos Silva, Alice ^b,d  

^a UNIVERSITY OF PORTO   (Portugal)

^b INSTITUTO DE INVESTIGAÇÃO E FORMAÇÃO AVANÇADA EM CIÊNCIAS E TECNOLOGIAS DA SAÚDE   (Portugal)

^c CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

^e UNIVERSITY OF BEIRA INTERIOR   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PHOTOSENSITIZING AGENT; PSORALEN;

ADULT; CARDIOVASCULAR DISEASE; FEMALE; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; PHOTOTHERAPY; PORTUGAL; PROCEDURES; PSORIASIS; RISK ASSESSMENT;

ADULT; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; FICUSIN; HUMANS; MALE; MIDDLE AGED; PHOTOSENSITIZING AGENTS; PORTUGAL; PSORIASIS; RISK ASSESSMENT; ULTRAVIOLET THERAPY;

EID: 84894226719     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2012.05856.x     Document Type: Note

References (9)

1. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-835.
2. Celik T, Iyisoy A, Celik M, et al. C-reactive protein in chronic heart failure: a new predictor of survival. Int J Cardiol 2009; 135: 396-397.
3. Boekholdt SM, Hack CE, Sandhu MS, et al. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003. Atherosclerosis 2006; 187: 415-422.
4. Liu Q, Tu T, Bai Z, et al. Elevated plasma pentraxin 3: a potential cardiovascular risk factor? Med Hypotheses 2011; 77: 1068-1070.
5. Jenny NS, Arnold AM, Kuller LH, et al. Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 2009; 29: 594-599.
6. Coimbra S, Oliveira H, Reis F, et al. C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy. J Eur Acad Dermatol Venereol 2010; 24: 789-796.
7. Bevelacqua V, Libra M, Mazzarino MC, et al. Long pentraxin 3: a marker of inflammation in untreated psoriatic patients. Int J Mol Med 2006; 18: 415-423.
8. Ctirad A, Lenka B, David P, et al. Goeckerman's therapy for psoriasis with special reference to serum pentraxin 3 level. Int J Dermatol 2008; 47: 1011-1014.
9. Lebwohl M, Ali S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001; 45: 487-498; quiz 99-502.